Literature DB >> 22342159

FUS-related proteinopathies: lessons from animal models.

Nicholas A Lanson1, Udai Bhan Pandey.   

Abstract

The recent identification of ALS-linked mutations in FUS and TDP-43 has led to a major shift in our thinking in regard to the potential molecular mechanisms of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). RNA-mediated proteinopathy is increasingly being recognized as a potential cause of neurodegenerative disorders. FUS and TDP-43 are structurally and functionally similar proteins. FUS is a DNA/RNA binding protein that may regulate aspects of RNA metabolism, including splicing, mRNA processing, and micro RNA biogenesis. It is unclear how ALS-linked mutations perturb the functions of FUS. This review highlights recent advances in understanding the functions of FUS and discusses findings from FUS animal models that provide several key insights into understanding the molecular mechanisms that might contribute to ALS pathogenesis. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22342159     DOI: 10.1016/j.brainres.2012.01.039

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  25 in total

Review 1.  Advances in understanding the molecular basis of frontotemporal dementia.

Authors:  Rosa Rademakers; Manuela Neumann; Ian R Mackenzie
Journal:  Nat Rev Neurol       Date:  2012-06-26       Impact factor: 42.937

2.  Structural and energetic basis of ALS-causing mutations in the atypical proline-tyrosine nuclear localization signal of the Fused in Sarcoma protein (FUS).

Authors:  Zi Chao Zhang; Yuh Min Chook
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-09       Impact factor: 11.205

3.  Pur-alpha regulates cytoplasmic stress granule dynamics and ameliorates FUS toxicity.

Authors:  J Gavin Daigle; Karthik Krishnamurthy; Nandini Ramesh; Ian Casci; John Monaghan; Kevin McAvoy; Earl W Godfrey; Dianne C Daniel; Edward M Johnson; Zachary Monahan; Frank Shewmaker; Piera Pasinelli; Udai Bhan Pandey
Journal:  Acta Neuropathol       Date:  2016-01-04       Impact factor: 17.088

Review 4.  Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects.

Authors:  Glenda Halliday; Eileen H Bigio; Nigel J Cairns; Manuela Neumann; Ian R A Mackenzie; David M A Mann
Journal:  Acta Neuropathol       Date:  2012-08-10       Impact factor: 17.088

5.  Ubiquilin-2 (UBQLN2) binds with high affinity to the C-terminal region of TDP-43 and modulates TDP-43 levels in H4 cells: characterization of inhibition by nucleic acids and 4-aminoquinolines.

Authors:  Joel A Cassel; Allen B Reitz
Journal:  Biochim Biophys Acta       Date:  2013-03-27

Review 6.  RNA-binding proteins associated molecular mechanisms of motor neuron degeneration pathogenesis.

Authors:  Anna Y Tang
Journal:  Mol Biotechnol       Date:  2014-09       Impact factor: 2.695

Review 7.  The role of FUS gene variants in neurodegenerative diseases.

Authors:  Hao Deng; Kai Gao; Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2014-05-20       Impact factor: 42.937

Review 8.  Fused in Sarcoma Neuropathology in Neurodegenerative Disease.

Authors:  Ian R A Mackenzie; Manuela Neumann
Journal:  Cold Spring Harb Perspect Med       Date:  2017-12-01       Impact factor: 6.915

Review 9.  TDP-43/FUS in motor neuron disease: Complexity and challenges.

Authors:  Erika N Guerrero; Haibo Wang; Joy Mitra; Pavana M Hegde; Sara E Stowell; Nicole F Liachko; Brian C Kraemer; Ralph M Garruto; K S Rao; Muralidhar L Hegde
Journal:  Prog Neurobiol       Date:  2016-09-28       Impact factor: 11.685

10.  RNA-binding ability of FUS regulates neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules associated with FUS carrying ALS-linked mutations.

Authors:  J Gavin Daigle; Nicholas A Lanson; Rebecca B Smith; Ian Casci; Astha Maltare; John Monaghan; Charles D Nichols; Dmitri Kryndushkin; Frank Shewmaker; Udai Bhan Pandey
Journal:  Hum Mol Genet       Date:  2012-12-20       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.